$26.62
0.97% yesterday
Nasdaq, Jan 06, 10:00 pm CET
ISIN
US00211Y4070
Symbol
ORKA

ARCA biopharma, Inc. Stock price

$26.62
-4.83 15.34% 1M
+13.33 100.30% 6M
-3.69 12.17% YTD
+6.10 29.73% 1Y
+10.16 61.75% 3Y
-0.03 0.13% 5Y
-507.76 95.02% 10Y
-1,263,666.59 100.00% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
-0.26 0.97%
ISIN
US00211Y4070
Symbol
ORKA
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$952.1m
Net debt
positive
Cash
$349.2m
Shares outstanding
48.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.7
Dividends
DPS
$19.36
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
-387.9% | -109.4%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-117.9m | $-124.4m
EBIT
$-117.9m | $-126.1m
Net Income
$-101.6m | $-106.6m
Free Cash Flow
$-84.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-90.5% | -41.3%
EBIT
-90.6% | -43.1%
Net Income
-66.5% | -27.3%
Free Cash Flow
-110.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
Financial Health
Equity Ratio
96.5%
Return on Equity
-21.9%
ROCE
-24.2%
ROIC
-
Debt/Equity
0.0
More
EPS
$-2.3
FCF per Share
$-1.7
Short interest
17.0%
Employees
-
Rev per Employee
-
Show more

Is ARCA biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a ARCA biopharma, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy
94%
Hold
6%

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
61% 61%
-
- Research and Development Expense 99 99
98% 98%
-
-118 -118
91% 91%
-
- Depreciation and Amortization 0.07 0.07
600% 600%
-
EBIT (Operating Income) EBIT -118 -118
91% 91%
-
Net Profit -102 -102
66% 66%
-

In millions USD.

Don't miss a Thing! We will send you all news about ARCA biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ARCA biopharma, Inc. Stock News

Neutral
GlobeNewsWire
about 12 hours ago
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P.
Positive
Seeking Alpha
about 22 hours ago
ORKA's main bet is by targeting psoriasis with ultra-durable biologics like ORKA-001 (IL-23) in Phase 2a and ORKA-002 (IL-17A/F) in Phase 1. ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that higher exposure may drive higher clearance and potential off-treatment remission.
Neutral
GlobeNewsWire
26 days ago
Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors
More ARCA biopharma, Inc. News

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office United States
CEO Lawrence Klein
Founded 1992
Website orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today